These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2060176)

  • 21. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonates for the prevention and treatment of osteoporosis.
    Maraka S; Kennel KA
    BMJ; 2015 Sep; 351():h3783. PubMed ID: 26333528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Secondary osteoporosis UPDATE. Rheumatoid arthritis and bone damage: trends in treatment].
    Tanaka Y
    Clin Calcium; 2010 May; 20(5):735-42. PubMed ID: 20445285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate.
    D'Eufemia P; Finocchiaro R; Celli M; Raccio I; Zambrano A; Tetti M; Smacchia P; Iacobini M
    Biomed Pharmacother; 2010 Apr; 64(4):271-4. PubMed ID: 20359847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [[Antiresorptive agents in the treatment of osteoporosis].
    Novak S
    Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prevention and prophylaxis of osteoporosis: options and limitations].
    Kudlacek S; Freudenthaler F; Willvonseder R
    Wien Med Wochenschr; 1999; 149(16-17):485-8. PubMed ID: 10627986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis.
    Treeprasertsuk S; Silveira MG; Petz JL; Lindor KD
    Am J Ther; 2011 Sep; 18(5):375-81. PubMed ID: 20460985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis.
    Simm PJ; Johannesen J; Briody J; McQuade M; Hsu B; Bridge C; Little DG; Cowell CT; Munns CF
    Bone; 2011 Nov; 49(5):939-43. PubMed ID: 21820091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease.
    Abitbol V; Briot K; Roux C; Roy C; Seksik P; Charachon A; Bouhnik Y; Coffin B; Allez M; Lamarque D; Chaussade S
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1184-9. PubMed ID: 17683996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention and treatment of osteoporosis in chronically ill children.
    Munns CF; Cowell CT
    J Musculoskelet Neuronal Interact; 2005; 5(3):262-72. PubMed ID: 16172517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Bisphosphonates in the treatment of osteoporosis].
    Fojtík Z; Kandusová M
    Vnitr Lek; 1997 Oct; 43(10):696-9. PubMed ID: 9601887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Bisphosphonate and mechanical stress on bone].
    Endo I; Matsumoto T
    Clin Calcium; 2008 Sep; 18(9):1321-6. PubMed ID: 18758038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
    N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of bone mineral density in adults with a history of juvenile chronic arthritis: a cross-sectional long-term followup study.
    Zak M; Hassager C; Lovell DJ; Nielsen S; Henderson CJ; Pedersen FK
    Arthritis Rheum; 1999 Apr; 42(4):790-8. PubMed ID: 10211895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abnormalities in the biochemical markers of bone turnover in children with juvenile chronic arthritis.
    Pereira RM; Falco V; Corrente JE; Chahade WH; Yoshinari NH
    Clin Exp Rheumatol; 1999; 17(2):251-5. PubMed ID: 10342056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of clodronate on immobilization bone loss.
    Minaire P; Depassio J; Berard E; Meunier PJ; Edouard C; Pilonchery G; Goedert G
    Bone; 1987; 8 Suppl 1():S63-8. PubMed ID: 2961357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification, prevention, and treatment of children with decreased bone mineral density.
    Szadek LL; Scharer K
    J Pediatr Nurs; 2014; 29(5):e3-14. PubMed ID: 24333239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention with clodronate of osteoporosis secondary to inhaled corticosteroid treatment in patients with chronic asthmatic bronchitis.
    Muratore M; Santacesaria G; Quarta E; Calcagnile F; Cosentino L; Muratore L
    Int J Clin Pharmacol Res; 2000; 20(3-4):61-4. PubMed ID: 11314239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
    Cruse LM; Valeriano J; Vasey FB; Carter JD
    J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.